Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (71)

« Back to Publications

Serum p-tau217 Is a Prognostic Indicator of Cognitive Impairment in Idiopathic REM Sleep Behavior Disorder.

Yan S. et al, (2026), Ann Neurol, 99, 912 - 921

Compartment-specific correlation of pathological α-synuclein in prodromal Parkinson's disease.

Röttgen S. et al, (2026), Parkinsonism Relat Disord, 144

Palindrome-mediated 16p13.3 triplications cause a recognizable neurodegenerative disorder with ataxia.

Fasham J. et al, (2026), Am J Hum Genet, 113, 221 - 233

In vivo validation of novel non-invasive PHP.eB AAVs as a potential therapeutic approach for alpha-synucleinopathies.

Fouka M. et al, (2025), Acta Neuropathol Commun, 13

Decade-Long Prodrome on Neuroimaging: Unique Insight into Probable Corticobasal Degeneration.

Tai XY. et al, (2025), Mov Disord, 40, 1727 - 1729

Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.

Gonzalez-Robles C. et al, (2025), Mov Disord, 40, 1307 - 1317

Working memory filtering at encoding and maintenance in healthy ageing, Alzheimer's and Parkinson's disease.

Toniolo S. et al, (2025), Sci Rep, 15

Single extracellular vesicle detection assay identifies membrane-associated α-synuclein as an early-stage biomarker in Parkinson's disease.

Yan S. et al, (2025), Cell Rep Med, 6

Detailed Analysis of ITPR1 Missense Variants Guides Diagnostics and Therapeutic Design.

Tolonen JP. et al, (2024), Mov Disord, 39, 141 - 151

Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease.

Yan S. et al, (2024), JAMA Neurol, 81, 59 - 68

WORKING MEMORY FILTERING AT ENCODING AND MAINTENANCE IN HEALTHY AGEING, ALZHEIMER’S AND PARKINSON’S DISEASE

Toniolo S. et al, (2024)

Normal and pathogenic variation of RFC1 repeat expansions: implications for clinical diagnosis.

Dominik N. et al, (2023), Brain, 146, 5060 - 5069

Methodological considerations in neuronal extracellular vesicle isolation for α-synuclein biomarkers.

Yan S. et al, (2023), Brain, 146, e95 - e97

Heterozygous UCHL1 loss-of-function variants cause a neurodegenerative disorder with spasticity, ataxia, neuropathy, and optic atrophy.

Park J. et al, (2023), Genet Med, 25

Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.

Foltynie T. et al, (2023), Brain, 146, 2717 - 2722

Load More

1
2
3
4
5